A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Identifieur interne : 000448 ( Ncbi/Merge ); précédent : 000447; suivant : 000449A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Auteurs : Anthony. Nicholas [États-Unis] ; Rupam Borgohain [Inde] ; Pedro Chaná [Chili] ; Erwin Surmann [Allemagne] ; Emily. Thompson [Royaume-Uni] ; Lars Bauer [Allemagne] ; John Whitesides [États-Unis] ; Lawrence. Elmer [États-Unis]Source :
- Journal of Parkinson's disease ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Tetrahydronaphthalenes, Thiophenes.
- drug therapy : Parkinson Disease.
- Administration, Cutaneous, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Previous phase III studies in patients with advanced Parkinson's disease (PD) not adequately controlled on levodopa demonstrated significant reduction of 'off' time with rotigotine transdermal system up to 16 mg/24 h. However, the minimal effective dose has not been established.
DOI: 10.3233/JPD-130320
PubMed: 24643203
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000029
- to stream PubMed, to step Curation: 000029
- to stream PubMed, to step Checkpoint: 000039
Links to Exploration step
pubmed:24643203Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.</title><author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony" last="Nicholas">Anthony. Nicholas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Borgohain, Rupam" sort="Borgohain, Rupam" uniqKey="Borgohain R" first="Rupam" last="Borgohain">Rupam Borgohain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Nizam's Institute of Medical Sciences, Andhra Pradesh, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Neurology, Nizam's Institute of Medical Sciences, Andhra Pradesh</wicri:regionArea><wicri:noRegion>Andhra Pradesh</wicri:noRegion></affiliation></author><author><name sortKey="Chana, Pedro" sort="Chana, Pedro" uniqKey="Chana P" first="Pedro" last="Chaná">Pedro Chaná</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Universidad de Santiago de Chile, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Department of Neurology, Universidad de Santiago de Chile, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name><affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Emily L" sort="Thompson, Emily L" uniqKey="Thompson E" first="Emily" last="Thompson">Emily. Thompson</name><affiliation wicri:level="3"><nlm:affiliation>Evidence Scientific Solutions Ltd, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Evidence Scientific Solutions Ltd, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bauer, Lars" sort="Bauer, Lars" uniqKey="Bauer L" first="Lars" last="Bauer">Lars Bauer</name><affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion></affiliation></author><author><name sortKey="Whitesides, John" sort="Whitesides, John" uniqKey="Whitesides J" first="John" last="Whitesides">John Whitesides</name><affiliation wicri:level="2"><nlm:affiliation>UCB Pharma, Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Pharma, Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Elmer, Lawrence W" sort="Elmer, Lawrence W" uniqKey="Elmer L" first="Lawrence" last="Elmer">Lawrence. Elmer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Toledo, Toledo, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Toledo, Toledo, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24643203</idno><idno type="pmid">24643203</idno><idno type="doi">10.3233/JPD-130320</idno><idno type="wicri:Area/PubMed/Corpus">000029</idno><idno type="wicri:Area/PubMed/Curation">000029</idno><idno type="wicri:Area/PubMed/Checkpoint">000039</idno><idno type="wicri:Area/Ncbi/Merge">000448</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.</title><author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony" last="Nicholas">Anthony. Nicholas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Borgohain, Rupam" sort="Borgohain, Rupam" uniqKey="Borgohain R" first="Rupam" last="Borgohain">Rupam Borgohain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Nizam's Institute of Medical Sciences, Andhra Pradesh, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Neurology, Nizam's Institute of Medical Sciences, Andhra Pradesh</wicri:regionArea><wicri:noRegion>Andhra Pradesh</wicri:noRegion></affiliation></author><author><name sortKey="Chana, Pedro" sort="Chana, Pedro" uniqKey="Chana P" first="Pedro" last="Chaná">Pedro Chaná</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Universidad de Santiago de Chile, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Department of Neurology, Universidad de Santiago de Chile, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name><affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Emily L" sort="Thompson, Emily L" uniqKey="Thompson E" first="Emily" last="Thompson">Emily. Thompson</name><affiliation wicri:level="3"><nlm:affiliation>Evidence Scientific Solutions Ltd, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Evidence Scientific Solutions Ltd, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bauer, Lars" sort="Bauer, Lars" uniqKey="Bauer L" first="Lars" last="Bauer">Lars Bauer</name><affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion><wicri:noRegion>Monheim am Rhein</wicri:noRegion></affiliation></author><author><name sortKey="Whitesides, John" sort="Whitesides, John" uniqKey="Whitesides J" first="John" last="Whitesides">John Whitesides</name><affiliation wicri:level="2"><nlm:affiliation>UCB Pharma, Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Pharma, Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Elmer, Lawrence W" sort="Elmer, Lawrence W" uniqKey="Elmer L" first="Lawrence" last="Elmer">Lawrence. Elmer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Toledo, Toledo, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Toledo, Toledo, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author></analytic><series><title level="j">Journal of Parkinson's disease</title><idno type="e-ISSN">1877-718X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Tetrahydronaphthalenes (administration & dosage)</term><term>Thiophenes (administration & dosage)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Tetrahydronaphthalenes</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous phase III studies in patients with advanced Parkinson's disease (PD) not adequately controlled on levodopa demonstrated significant reduction of 'off' time with rotigotine transdermal system up to 16 mg/24 h. However, the minimal effective dose has not been established.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24643203</PMID><DateCreated><Year>2014</Year><Month>09</Month><Day>03</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>27</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1877-718X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Journal of Parkinson's disease</Title><ISOAbbreviation>J Parkinsons Dis</ISOAbbreviation></Journal><ArticleTitle>A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>361-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JPD-130320</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous phase III studies in patients with advanced Parkinson's disease (PD) not adequately controlled on levodopa demonstrated significant reduction of 'off' time with rotigotine transdermal system up to 16 mg/24 h. However, the minimal effective dose has not been established.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This international, randomized, double-blind, placebo-controlled study (SP921; NCT00522379) investigated rotigotine dose response up to 8 mg/24 h.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with advanced idiopathic PD (≥2.5 h of daily 'off' time on stable doses of levodopa) were randomized 1:1:1:1:1 to receive rotigotine 2, 4, 6, or 8 mg/24 h or placebo, titrated over 4 weeks and maintained for 12 weeks. The primary efficacy variable was change from baseline to end of maintenance in absolute time spent 'off'.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">409/514 (80%) randomized patients completed maintenance. Mean (±SD) baseline daily 'off' times (h/day) were placebo: 6.4 (±2.5), rotigotine 2-8 mg/24 h: 6.4 (±2.6). Rotigotine 8 mg/24 h was the minimal dose to significantly reduce 'off' time versus placebo. LS mean (±SE) absolute change in daily 'off' time (h/day) from baseline was -2.4 (±0.28) with rotigotine 8 mg/24 h, and -1.5 (±0.26) with placebo; absolute change in 'off' time in the 8 mg/24 h group compared with placebo was -0.85 h/day (95% CI -1.59, -0.11; p = 0.024). There was an apparent dose-dependent trend. Adverse events (AEs) reported at a higher incidence in the rotigotine 8 mg/24 h group versus placebo included application site reactions, nausea, dry mouth, and dyskinesia; there was no worsening of insomnia, somnolence, orthostatic hypotension, confusional state or hallucinations, even in patients ≥75 years of age.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The minimal statistically significant effective dose of rotigotine to reduce absolute 'off' time was 8 mg/24 h. The AE profile was similar to previous studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Anthony P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borgohain</LastName><ForeName>Rupam</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nizam's Institute of Medical Sciences, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaná</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universidad de Santiago de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surmann</LastName><ForeName>Erwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UCB Pharma, Monheim am Rhein, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Emily L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Evidence Scientific Solutions Ltd, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UCB Pharma, Monheim am Rhein, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitesides</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UCB Pharma, Raleigh, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmer</LastName><ForeName>Lawrence W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Toledo, Toledo, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SP921 Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Parkinsons Dis</MedlineTA><NlmUniqueID>101567362</NlmUniqueID><ISSNLinking>1877-7171</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>92206-54-7</RegistryNumber><NameOfSubstance UI="C047508">N 0437</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000279">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013764">Tetrahydronaphthalenes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013876">Thiophenes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">dopamine receptor agonist</Keyword><Keyword MajorTopicYN="N">dose-response relationship</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword><Keyword MajorTopicYN="N">rotigotine</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Punit</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altamirano</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alurkar</LastName><ForeName>Anand</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blankenship</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bremer</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brick</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckler</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burch</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burkholder</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandran</LastName><ForeName>Suresh</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cochran</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flitman</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrison</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glyman</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gongora-Rivera</LastName><ForeName>Juan-Fernando</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grainger</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greeley</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Alida</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamill</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermanowicz</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houghton</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhigao</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hull</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hull</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ichaporia</LastName><ForeName>Nasli</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ironside</LastName><ForeName>Brett</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isaacson</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennings</LastName><ForeName>Danna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keshava</LastName><ForeName>B S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kishore</LastName><ForeName>Asha</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreitzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leopold</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesch</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeWitt</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lincoln</LastName><ForeName>Annie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margolin</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Fredrick</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzetti</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>McElveen</LastName><ForeName>W Alvin</ForeName><Initials>WA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muthane</LastName><ForeName>Uday</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>Marshall</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nausieda</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nellikunja</LastName><ForeName>Shankar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieves</LastName><ForeName>Anette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parashos</LastName><ForeName>Sotirios</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patton</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauranik</LastName><ForeName>Apoorva</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potts</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramaratnam</LastName><ForeName>Sridharan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rangel-Guerra</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reyes-Morales</LastName><ForeName>Sarug</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qutubuddin</LastName><ForeName>Abu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racette</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samanta</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sankhla</LastName><ForeName>Charulata</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarma</LastName><ForeName>G R K</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sauter</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaeffer</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silver</LastName><ForeName>Dee</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simuni</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spector</LastName><ForeName>Sidney</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steingo</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struck</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sutton</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swope</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taber</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarsy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truong</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varma</LastName><ForeName>Navin</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidic</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vine</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waters</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wells</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24643203</ArticleId><ArticleId IdType="pii">1G0H131P48588665</ArticleId><ArticleId IdType="doi">10.3233/JPD-130320</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Chili</li><li>Inde</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Alabama</li><li>Angleterre</li><li>Caroline du Nord</li><li>Grand Londres</li><li>Ohio</li></region><settlement><li>Londres</li></settlement></list><tree><country name="États-Unis"><region name="Alabama"><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony" last="Nicholas">Anthony. Nicholas</name></region><name sortKey="Elmer, Lawrence W" sort="Elmer, Lawrence W" uniqKey="Elmer L" first="Lawrence" last="Elmer">Lawrence. Elmer</name><name sortKey="Whitesides, John" sort="Whitesides, John" uniqKey="Whitesides J" first="John" last="Whitesides">John Whitesides</name></country><country name="Inde"><noRegion><name sortKey="Borgohain, Rupam" sort="Borgohain, Rupam" uniqKey="Borgohain R" first="Rupam" last="Borgohain">Rupam Borgohain</name></noRegion></country><country name="Chili"><noRegion><name sortKey="Chana, Pedro" sort="Chana, Pedro" uniqKey="Chana P" first="Pedro" last="Chaná">Pedro Chaná</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name></noRegion><name sortKey="Bauer, Lars" sort="Bauer, Lars" uniqKey="Bauer L" first="Lars" last="Bauer">Lars Bauer</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Thompson, Emily L" sort="Thompson, Emily L" uniqKey="Thompson E" first="Emily" last="Thompson">Emily. Thompson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000448 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000448 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:24643203
|texte= A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24643203" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |